The Role of Long Pentraxin 3, A New Inflammatory Mediator in Inflammatory Responses

DOI Web Site 1 Citations 61 References
  • OKUTANI Daisuke
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry Thoracic Surgery, Toronto General Hospital Research Institute, University of Toronto

Bibliographic Information

Other Title
  • 新しいメディエーター，Ｐｅｎｔｒａｘｉｎ　３の炎症反応における役割

Search this article

Abstract

  Pentraxin 3 (PTX3) is suggested to play important roles in the innate resistance against pathogens, regulation of inflammatory reactions, and clearance of apoptotic cells. PTX3 is the first long pentraxin identified. Long pentraxin shares a C-terminal pentraxin domain with the classical short pentraxin (C-reactive protein, serum amyloid P), but holds an unrelated N-terminal domain that is unique to the long pentraxin. While the short pentraxin is produced only in the liver, PTX3 is made by diverse types of cells, prominently endothelial cells and macrophage, in response to inflammatory signals. Unlike the short pentraxin, the expression of PTX3 in multiple types of tissue cells implies a mechanism for local amplification of innate resistance at the site of infection and inflammation. PTX3 plasma levels are very low in normal subjects but are rapidly increased by inflammatory conditions resulting from a wide range of diseased states, from infection to autoimmune and degenerative disorders. Critically ill patients show elevated circulating levels of PTX3 which are determined by the severity of the disease. Clinical evidence has demonstrated that the elevated PTX3 levels might be a useful early and sensitive marker for severely ill patients. Further studies will definitely be needed to deepen our understanding of PTX3.<br>

Journal

Citations (1)*help

See more

References(61)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top